This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Bradley Lunde, Ph.D.
Group Leader, Antibody Engineering at Adimab


Bradley Lunde is a group leader in the Antibody Engineering department at Adimab LLC. He is one of several key contributors to the development of the yeast HCAb platform and the discovery and development of Adimab’s CD28 offering. He received his PhD from the University of Washington in 2009 and worked in Germany prior to joining Adimab in 2015.

Agenda Sessions

  • Development of a Versatile, Synthetic, Heavy Chain-only Antibody Platform in a Yeast-based Therapeutic Discovery Platform